3.5.1.60: N-(long-chain-acyl)ethanolamine deacylase
This is an abbreviated version!
For detailed information about N-(long-chain-acyl)ethanolamine deacylase, go to the full flat file.
Reaction
Synonyms
acylethanolamine acid amidase, amidase, acylethanolamine, hNAAA, N-acylethanolamine acid amidase, N-acylethanolamine amidohydrolase, N-acylethanolamine-hydrolyzing acid amidase, N-acylethanolaminehydrolyzing acid amidase, NAAA, Nacylethanolamine acid amidase, NAE-hydrolyzing acid amidase
ECTree
Advanced search results
Application
Application on EC 3.5.1.60 - N-(long-chain-acyl)ethanolamine deacylase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
drug development
medicine
modulation of the tissue levels of palmitoylethanolamide by inhibition of enzymes responsible for the breakdown of this lipid mediator, including the N-acylethanolamine acid amidase, may represent therefore a therapeutic strategy for the treatment of pain and inflammation
pharmacology
drug development
inhibitors against N-acylethanolamine-hydrolyzing acid amidase are promising tools against bladder cancer
drug development
-
NAAA is a promising target for the development of effective and safe treatments for atopic dermatitis and other inflammatory disorders of the skin
drug development
the cysteine hydrolase, N-acylethanolamine acid amidase (NAAA) is a promising target for analgesic and anti-inflammatory drugs
drug development
-
NAAA is a promising target for the development of effective and safe treatments for atopic dermatitis and other inflammatory disorders of the skin
-
potential of blocking N-acylethanolamines like palmitoylethanolamide or N-arachidonlyethanolamine (anandamide) from enzymatic degradation via enzyme inhibition as a strategy for pain treatment
pharmacology
NAAA inhibitor F215 is a therapeutic agent for osteoarthritis. The therapeutic effects of F215 are blocked by the PPAR-alpha antagonist MK886
pharmacology
NAAA inhibitor F215 is a therapeutic agent for osteoarthritis. The therapeutic effects of F215 are blocked by the PPAR-alpha antagonist MK886